Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 2,120 trials

High-Risk Prostate Cancer: THUNDER Trial

We are studying new diagnostic tracers and treatment options for men with high-risk prostate cancer. The goal is to see if these methods improve survival and quality of life compared to standard treatments.

Prostate Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesOncologyUrology

Richter Syndrome: GLOfitamab with Chemotherapy

We are studying a new treatment combining GLOfitamab with standard chemotherapy for patients with Richter syndrome. The goal is to see if this combination improves treatment response and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Triple-Negative Breast Cancer: Tiragolumab and Atezolizumab with Chemotherapy

We are studying a combination of two immunotherapy drugs with chemotherapy for patients with triple-negative breast cancer. This trial aims to evaluate the treatment's effectiveness and safety in both early and advanced stages of the disease.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Serious Bacterial Infections in Children: Aztreonam-Avibactam Study

We are investigating a new treatment for serious gram-negative bacterial infections in children aged 9 months to under 18 years. The study compares this treatment to the best available therapy to assess safety and effectiveness.

Hospital-Acquired PneumoniaVentilator-Associated PneumoniaComplicated Gram-Negative Bacterial Infections≤3 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPediatrics

Atopic Dermatitis: Rocatinlimab Study

We are investigating the long-term safety and effectiveness of rocatinlimab for adults and adolescents with moderate-to-severe atopic dermatitis. The study compares the treatment's effects to a placebo in those who have previously responded to the medication.

Atopic DermatitisConfirmation phase (III)Investigational MedicinesCost ReimbursementAllergologyDermatology

Graft-Versus-Host Disease: Anti-Lymphocyte Serum Study

We are studying how the anti-lymphocyte serum works in children and adults receiving stem cell transplants. This research aims to improve prevention strategies for graft-versus-host disease.

Stem Cell Transplant1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyPediatrics

Ovarian Cancer: Mirvetuximab Soravtansine with Bevacizumab

We are studying a new treatment combining mirvetuximab soravtansine and bevacizumab for adults with recurrent ovarian cancer who have not progressed after chemotherapy. The goal is to see if this combination helps patients live longer without their cancer worsening.

Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Long-Term Safety of Miltenyi CAR T Cell Therapy

We are studying the long-term effects of Miltenyi CAR T cell therapy on patients, especially children. This includes monitoring safety, disease progression, and overall survival.

Unresectable Stage III or IV MelanomaRelapsed or Refractory B Cell Non-Hodgkin's LymphomaRelapsed or Refractory CD20 Positive B-Cell Non-Hodgkin’s Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyHematologyOncology

Kidney Transplant: Belatacept vs. Calcineurin Inhibitors

We are studying whether switching to a new immunosuppressive medication helps adolescent kidney transplant recipients maintain their health better than staying on their current treatment. This trial focuses on patients aged 12 to under 18 years.

Kidney Transplant>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Continued Treatment with Parsaclisib for Blood Disorders

We are providing ongoing treatment for patients who have previously participated in studies of parsaclisib. The goal is to evaluate the safety of this medication alone or with other therapies.

Advanced CancerAutoimmune Hemolytic AnemiaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Low-Grade Gliomas: 18F-FDOPA PET Imaging Study

We are exploring whether a new imaging technique can better identify aggressive features in suspected low-grade gliomas without MRI contrast enhancement. This may help improve diagnosis and treatment planning for patients.

Low Grade GliomaConfirmation phase (III)No PlaceboInvestigational MedicinesNeurologyOncology

Neuroblastoma: Comparing PET-CT and SPECT-CT Scans

We are studying whether a new PET-CT scan can better detect lesions in patients with neuroblastoma compared to a standard SPECT-CT scan. This may help improve diagnosis and treatment options for patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Advanced Non-Clear Cell Kidney Cancer: XL092 + Nivolumab

We are studying a new treatment combination for patients with advanced or metastatic non-clear cell kidney cancer. The goal is to see if it works better and is safer than the standard treatment.

Advanced Non-Clear Cell Renal Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

T-Cell Lymphoma: Autologous Stem Cell Transplantation Study

We are investigating whether autologous stem cell transplantation helps patients with T-cell lymphoma who have responded well to initial chemotherapy. This study aims to see if it improves their chances of staying cancer-free longer.

Peripheral T-cell Lymphoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOncology

GD2 Positive Solid Cancers: GD2IL18CART Treatment

We are testing a new therapy called GD2IL18CART for patients with relapsed or hard-to-treat GD2 positive solid cancers. The study aims to assess safety, find the right dose, and evaluate how well the treatment works.

NeuroblastomaAdvanced Breast CancerEwing Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Metreleptin for Young Children with Generalized Lipodystrophy

We are studying whether metreleptin can help children under 6 years old with generalized lipodystrophy and related diabetes. The trial will also look at its effects on quality of life and other health markers.

Generalized Lipodystrophy1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyEndocrinology

Mantle Cell Lymphoma: Venetoclax with Ibrutinib and Rituximab

We are studying a new treatment combination for patients with Mantle Cell Lymphoma who cannot undergo high-dose therapy. The goal is to see how well it works compared to standard chemotherapy.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Marginal Zone Lymphoma: Mosunetuzumab-Lenalidomide Study

We are investigating whether the combination of Mosunetuzumab and Lenalidomide is more effective than standard treatments for patients with relapsed or refractory Marginal Zone Lymphoma. The study aims to assess how well this new treatment works and its safety.

Marginal Zone Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Myeloma: [68Ga]Ga-PentixaFor PET Imaging Study

We are studying a new imaging method to see how accurately it detects myeloma at the beginning of treatment. This may help improve risk assessment and disease management for patients.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Remifentanil for Intubation in Newborns

We are studying the best dose of remifentanil to safely sedate newborns during intubation. Our goal is to ensure effective sedation with minimal side effects.

Stable Neonates Requiring Intubation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics